$75.55
1.722.33%
Last update: Jun 24, 9:28 AM
TransMedics Group Inc Stock Guidance
TMDXNASDAQ
TransMedics Group (TMDX) last issued guidance on May 5, 2026 for fiscal year 2026. The company guided revenue in the range of $727.00M - $757.00M for the period.
Compared to prior guidance, TransMedics Group maintained its revenue forecast from a prior range of $727.00M - $757.00M.
TransMedics Group has issued 17 guidance updates between August 1, 2022 and May 5, 2026. During this period, the company raised its outlook 12 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
Latest Guidance Date
May 5, 2026
Guidance Period
Full Year 2026
Revenue Guidance Range
$727.00M - $757.00M
TransMedics Group Guidance History
Review all historical guidance issued by TransMedics Group, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for TransMedics Group (TMDX)?
The most recent guidance for TransMedics Group (TMDX) was reported on May 5, 2026 for the fiscal year 2026. TransMedics Group forecasted revenue between $727.00M and $757.00M for the period.
What revenue range did TransMedics Group (TMDX) guide for?
TransMedics Group (TMDX) guided revenue in the range of $727.00M to $757.00M for the fiscal year 2026.
Did TransMedics Group (TMDX) raise or lower guidance?
TransMedics Group (TMDX) maintained its revenue guidance from a prior range of $727.00M - $757.00M to $727.00M - $757.00M for the fiscal year 2026.
When did TransMedics Group (TMDX) last issue guidance?
TransMedics Group (TMDX) last issued guidance on May 5, 2026 for the fiscal year 2026.
